Allergic Rhinitis Management in Children

Initial Diagnostic Evaluation

The American Academy of Allergy, Asthma, and Immunology recommends specific allergen identification through skin prick testing or serum-specific IgE testing to common inhalant allergens for children with recurrent symptoms and elevated IgE levels 1, 2
Assessment for comorbid conditions, including asthma and atopic dermatitis, is necessary for children with persistent allergic rhinitis symptoms 1, 3

The American College of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the most effective pharmacologic treatment for pediatric allergic rhinitis, with options including mometasone furoate, fluticasone propionate, or budesonide once daily 3
Adding a second-generation oral antihistamine, such as cetirizine 5-10 mg daily, can provide comprehensive symptom control for children with allergic rhinitis 3, 4
Continuous daily dosing of medications is more effective than intermittent use for perennial symptoms due to ongoing allergen exposure 3, 4

The American Academy of Allergy, Asthma, and Immunology recommends identifying and minimizing exposure to specific allergens, such as dust mites, molds, and animal dander, to reduce symptoms of allergic rhinitis 1, 3, 5
Controlling indoor humidity, repairing water leaks, and improving ventilation in bathrooms and kitchens can help reduce mold sensitivity 1, 5
Removing pets from the home or keeping them out of the bedroom and using HEPA air filters can help reduce animal allergen exposure 1, 2

The American Academy of Pediatrics recommends evaluating treatment response after 2-4 weeks of continuous therapy for children with allergic rhinitis 3, 6
Consider increasing intranasal corticosteroid dose or adding intranasal antihistamine for partial improvement, and reassess diagnosis and verify medication adherence for minimal improvement 3, 7
Allergen immunotherapy can be considered for persistent symptoms despite optimal medical therapy after 3-6 months, and provides long-term benefits including prevention of new allergen sensitivities and reduced progression to asthma 8, 9, 10

The American Thoracic Society recommends evaluating for underlying asthma in children with cough and allergic rhinitis symptoms, and considering spirometry if age-appropriate and symptoms suggest lower airway involvement 1, 11, 5
Treating allergic rhinitis with intranasal corticosteroids may reduce asthma symptoms and prevent asthma development 11, 8

The American Academy of Allergy, Asthma, and Immunology recommends classifying allergic rhinitis as intermittent versus persistent, and mild versus moderate-to-severe based on symptom frequency and impact on school performance and quality of life 12, 13

The American Academy of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the first-line treatment for children 4 years and older with moderate-to-severe allergic rhinitis, as they are the most effective medication class for controlling nasal symptoms and improving quality of life 12
Second-generation antihistamines, such as cetirizine, loratadine, or desloratadine, are effective for histamine-mediated symptoms, including itching, sneezing, and rhinorrhea, especially in seasonal/pollen-induced rhinitis, and avoid the sedation and cognitive impairment associated with first-generation agents 14

The American Academy of Allergy, Asthma, and Immunology recommends subcutaneous immunotherapy (SCIT) for children with allergic rhinitis, with potential benefits including symptom reduction and prevention of asthma development 15, 16
Sublingual immunotherapy (SLIT) is conditionally recommended for pollen-induced allergic rhinitis in children, with moderate-quality evidence, but should only be administered in rigorously designed clinical trials for dust mite-induced allergic rhinitis due to very low-quality evidence 15, 16
Immunotherapy provides disease-modifying effects, including prevention of new allergen sensitivities and reduced progression to asthma, with treatment duration typically 3-5 years for sustained benefit 17